Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
may mediate vascular cell growth. Additionally we are shipping and many more products for this protein.
Showing 10 out of 65 products:
Human Polyclonal DCBLD2 Primary Antibody for FACS, WB - ABIN657748
Marroni, Pfeufer, Aulchenko, Franklin, Isaacs, Pichler, Wild, Oostra, Wright, Campbell, Witteman, Kääb, Hicks, Gyllensten, Rudan, Meitinger, Pattaro, van Duijn, Wilson, Pramstaller: A genome-wide association scan of RR and QT interval duration in 3 European genetically isolated populations: the EUROSPAN project. in Circulation. Cardiovascular genetics 2009
Show all 2 references for ABIN657748
Human Polyclonal DCBLD2 Primary Antibody for IHC, IHC (p) - ABIN4304485
Fukumoto, Kinoshita, Hanazawa, Kikkawa, Chiyomaru, Enokida, Yamamoto, Goto, Nishikawa, Nakagawa, Okamoto, Seki: Identification of tumour suppressive microRNA-451a in hypopharyngeal squamous cell carcinoma based on microRNA expression signature. in British journal of cancer 2014
Knockdown of the Esdn homolog (dcbld2) in zebrafish impaired normal vascular development.
phosphorylation of DCBLD2 Y750 recruited TRAF6 (show TRAF6 Antibodies), leading to increased TRAF6 (show TRAF6 Antibodies) E3 ubiquitin ligase (show MUL1 Antibodies) activity and subsequent activation of AKT (show AKT1 Antibodies), thereby enhancing EGFR (show EGFR Antibodies)-driven tumorigenesis
ESDN associates with VEGFR-2 and regulates its complex formation with negative regulators of VEGF signaling, protein tyrosine phosphatases PTP1B and TC-PTP, and VE-cadherin.
SFK activity was shown to be sufficient, but not required for the interaction between ESDN and the CrkL-SH2 domain
ESDN and AP-2g (show TFAP2C Antibodies) expression is lower in thick melanomas, it is associated with unfavourable histo-pathological parameters (increased vascularity, vascular invasion and mitoses) and correlates with a shorter DFS (show FST Antibodies) like for AP-2a.
These findings suggest that DCBLD2 could be a potential marker and drug target for treatment of nasal polyposis in Korean asthma patients.
Seven SNPs (rs1371687, rs7615856, rs828621, rs828618, rs828616, rs1062196, and rs8833) and one haplotype (DCBLD2-ht1) show associations with susceptibility to AERD.
The full-length signal peptides of DCBLD2 is functional and furthermore that the C-domains are sufficient and essential for ER targeting, whereas the N-domains are dispensable. Thus, the N-domains are available for additional functions.
our study is the first to identify and validate Endofin (show ZFYVE16 Antibodies), DCBLD2, and KIAA0582 as part of a complex EGF (show EGF Antibodies) phosphotyrosine signaling network
ESDN expression was significantly higher in proliferating, as compared to growth-arrested cells. ESDN overexpression in VSMC led to a decline in growth curves, while ESDN knock down had the opposite effect.
These data suggest that down-regulation of DCBLD2, often associated with promoter hypermethylation, is a frequent event that may be related to the development of gastric cancer.
Deletion of Esdn in the mouse interfered with adult and developmental angiogenesis.
may mediate vascular cell growth
discoidin, CUB and LCCL domain containing 2
, discoidin, CUB and LCCL domain-containing protein 2-like
, CUB, LCCL and coagulation factor V/VIII-homology domains protein 1
, coagulation factor V/VIII-homology domains protein 1
, discoidin, CUB and LCCL domain-containing protein 2
, endothelial and smooth muscle cell-derived neuropilin-like protein